All In Biotech

NDA 022041 · Btg Intl

Cyanokit

Hydroxocobalamin · Injection · Antidote

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Dec 15, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

294

72 Phase 3, 20 recruiting

FAERS reports

4,238

3,876 serious, 315 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 27, 2023.

CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. ( 1 )

Mechanism: Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 15, 2006 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
2 products under this application
  • CYANOKIT · HYDROXOCOBALAMIN 5GM/VIAL (5GM/KIT) · INJECTABLE, INJECTION · Prescription
  • CYANOKIT · HYDROXOCOBALAMIN 2.5GM/VIAL (5GM/KIT) · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydroxocobalamin" as an intervention, any sponsor and status, largest first.

All 294 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury211
  • nausea207
  • diarrhoea205
  • dyspnoea190
  • dizziness178
  • vomiting167
  • off label use166
  • malaise151
  • hyponatraemia138
  • fatigue136
  • confusional state129
  • rash120

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20059
200611
200719
200842
200932
201032
201177
201285
201398
2014149
2015152
2016218
2017252
2018346
2019393
2020377
2021278
2022320
2023350
2024368
2025305
2026319

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 16, 2026

    Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 44 on PubMed

Sponsor: Btg Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.